Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study

Fig. 2

Switching from RASIs to CCBs, other antihypertensive drugs (OADs), or no antihypertensive treatment during the first 3 days since hospital admission (patients with uncertain discontinuation were excluded). Of all outpatient RASI users, 45.6% continued with RASIs (alone or combined with CCBs or OADs), 29.2% were switched to CCBs or OADs, and 25.3% were left without any antihypertensive treatment. Dynamic visualization available in: https://public.flourish.studio/visualisation/4808393/. Abbreviations: CCBs calcium-channel blockers, OADs other antihypertensive drugs (different from RASIs or CCBs), RASIs renin-angiotensin system inhibitors. RASIs+CCB combined use with OADs allowed, RASIs+OADs use of CCBs excluded, CCBs alone or combined with OADs and RASIs excluded, OADs use of RASIs and CCBs excluded

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us